The Cost of Mistiming: Where resources are lost when time is ignored.

A large part of healthcare cost does not arise from wrong decisions, but from mistimed ones.Recognizing time as biology is not optional—it is an economic necessity. Healthcare systems invest vast resources in treatments that fail in trials and in clinical practice. These failures are usually interpreted as biological—wrong targets, insufficient mechanisms, or complexity beyond current understanding. This paper proposes a complementary explanation: that a substantial portion of these losses arises from mistimed intervention rather than incorrect action. From a systems-dynamic perspective, treatment effect is phase-dependent. Disease unfolds through evolving states of plasticity, regulation, and stability, and the same intervention can produce markedly different outcomes depending on when it is applied. When treatments are tested or used outside responsive phases, resources are spent on actions that cannot meaningfully alter system trajectory. This paper identifies where timing-blindness generates economic loss across three domains: drug development, clinical practice, and missed opportunity. It shows how phase mismatch can lead to failed trials, how escalation strategies can convert uncertainty into cost while obscuring system behavior, and how polypharmacy often reflects attempts to compensate for mistimed intervention. It also highlights the hidden cost of abandoned mechanisms and missed therapeutic windows. Rather than attempting exact economic quantification, the paper provides a structural analysis of where and why losses occur. It argues that a significant portion of healthcare inefficiency is not due to doing the wrong thing, but to doing the right thing at the wrong time. This work is part of the Timing & Failure series, which reframes treatment failure as a timing problem across biological systems, clinical interpretation, and trial design. Together, these papers propose that recognizing time as a biological variable is essential not only for improving outcomes, but for reducing structural waste in medicine.